Litigation Details for ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)
✉ Email this page to a colleague
ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)
| Docket | 2:20-cv-12470 | Date Filed | 2020-09-09 |
| Court | District Court, D. New Jersey | Date Terminated | 2023-08-30 |
| Cause | 28:1338 Patent Infringement | Assigned To | Madeline Cox Arleo |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 6,264,987; 7,919,499 | ||
| Attorneys | CHARLES MICHAEL LIZZA | ||
| Firms | Kean University | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-09-09 | External link to document | |||
| 2020-09-09 | 1 | Complaint | -Controlled Clinical Trial, "Alco- 6,264,987 B1 7/2001 Wright et al. … 3 process described in U.S. Pat. No. 6,264,987, by Wright et al., weight, more preferably… release include pore example, U.S. Pat. No. 6,264,987 to Wright, U.S. Pat. Nos. forming…expiration date of the ’499 patent, including any patent term extensions and/or patent term adjustments, and… of 28 PageID: 10 patent, including any patent term extensions and/or patent term adjustments, and | External link to document |
| 2020-09-09 | 207 | Brief | partes review Patent-in-Suit or U.S. Patent No. 7,919,499 to E. Ehrich,… Patent Trial and Appeal Board at the PTO PTO U.S. Patent and Trademark… the patent claims, specification, and prosecution history underlying the grant of the patent is plain… Post-Grant Review Decisions by the Patent Office ........................................…Ehrich, PTX-1 ’499 Patent POSA Person of ordinary skill in the art PTAB | External link to document |
| 2020-09-09 | 224 | Trial Brief | Wright et al., U.S. Patent No. 6,264,987, titled “Method for Wright …-1) ’499 Patent Patent Prosecution History of U.S. Patent No. 7,919,499… The ’499 Patent A. Overview of the ’499 Patent The ’499 Patent explains that… Patent-in-Suit U.S. Patent No. 7,919,499, titled “…17, 2005 (PTX-52) (PTX-179) Patent-in-suit The ’499 Patent | External link to document |
| 2020-09-09 | 229 | Trial Brief | ’499 Patent Prosecution Patent Prosecution History of U.S. Patent No. 7,919,499 (DTX-002)… Patent-in-Suit U.S. Patent No. 7,919,499, titled “Naltrexone …March 17, 2005 (PTX-52) (PTX-179) Patent-in-suit The ’499 Patent …pharmacokinetics (for whom the patent is written) has not just the patent claims …many, many patent cases (but not this one) involve genuine issues of infringement, and patents 4 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation Summary and Analysis: Alkermes, Inc. v. Teva Pharmaceutical Industries USA, Inc. (2:20-cv-12470)
More… ↓
